Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Curevac N.V.
Industry Sector: HealthTechnology
CEO: Alexander Zehnder, MD, MBA
Number Of Employees: 1,172
Enterprise Value: $531,340,374
PE Ratio: 5.09
Exchange/Ticker 1: NASDAQ:CVAC
Exchange/Ticker 2: N/A
Latest Market Cap: $628,056,832
BioCentury | Mar 4, 2025
Management Tracks
Head of R&D Robert Lenz to leave Neumora
Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more
BioCentury | Jan 28, 2025
Distillery Therapeutics
RUNX1 inhibition via dominant negative mRNA construct for vitreoretinal disease
BioCentury | Nov 5, 2024
Management Tracks
Alan Bash named president of Carvykti at Legend
Plus: CureVac hires Axel Malkomes as CFO; new CEOs at Coya, Libra; and updates from 4BIO, Memo and Alltrna
BioCentury | Aug 15, 2024
Management Tracks
CFO Kemula leaving CureVac
Plus: Chemify hires CBO to realize commercial ambitions and more from Biocartis and Estrella
BioCentury | Jul 12, 2024
Management Tracks
J.P. Morgan adds Joseph Siletto as managing partner
Plus: Fresenius and NS Pharma name new presidents, and updates from The Francis Crick Institute, CIRM, Nuvalent and more
BioCentury | Jul 8, 2024
Deals
Deals report: Lilly acquires Morphic, GSK gets full rights for mRNA vaccines from CureVac
Plus: Iaso gets full rights to Fucaso from Innovent, and updates from Genexine, EPD, Pentixapharm and Glycotope
BioCentury | Jul 3, 2024
Deals
CureVac reshapes deal with GSK, putting upfront cash toward cancer pipeline
Vaccine developer also cutting 30% of staff, adding years of cash runway
BioCentury | Apr 25, 2024
Management Tracks
Smart to lead Actym as CEO
Plus: Ramanayake joins CureVac and updates from Oruka, Madrigal and AusBiotech
BioCentury | Dec 20, 2023
Deals
Dec. 19 Quick Takes: Ionis, Otsuka in European deal for HAE therapy
Plus: Carmot spinout Kimia raises $55M series A round, CureVac tumbles on loss in patent case and more from Lassen, Atavistik, Crinetics, Merck and CSL
BioCentury | Jul 21, 2023
Management Tracks
Janssen vet Vratsanos joins Jnana as CMO
Plus: CureVac’s Splawski lands at Yarrow and updates from Genelux, Cour and more
Items per page:
1 - 10 of 105